Abstract

Background

Type D personality refers to a combination of simultaneously high levels of negative affectivity and social inhibition. The present study aimed to examine whether type D personality was independently associated with recurrent myocardial infarction or all-cause mortality in post-acute myocardial infarction patients, using any of the previously proposed methods for measuring type D personality.

Design

This was a prospective cohort study.

Methods

Utilising data from the Västmanland Myocardial Infarction Study, 946 post-acute myocardial infarction patients having data on the DS14 instrument used to measure type D personality were followed-up for recurrent myocardial infarction and all-cause mortality until 9 December 2015. Data were analysed using Cox regression, adjusted for established risk factors.

Results

In total, 133 (14.1%) patients suffered from type D personality. During a mean follow-up time for recurrent myocardial infarction of 5.7 (3.2) years, 166 (17.5%) patients were affected by recurrent myocardial infarction, of which 26 (15.7%) had type D personality, while during a mean follow-up time for all-cause mortality of 6.3 (2.9) years, 321 (33.9%) patients died, of which 42 (13.1%) had type D personality. After adjusting for established risk factors, type D personality was not significantly associated with recurrent myocardial infarction or all-cause mortality using any of the previously proposed methods for measuring type D personality. A weak association was found between the social inhibition part of type D personality and a decreased risk of all-cause mortality, but this association was not significant after taking missing data into account in a multiple imputation analysis.

Conclusions

No support was found for type D personality being independently associated with recurrent myocardial infarction or all-cause mortality in post-acute myocardial infarction patients, using any of the previously proposed methods for measuring type D personality.

Introduction

Cardiovascular diseases (CVDs) are the primary cause of death worldwide.1 Several clinical, biological, and psychosocial characteristics have been presented as risk factors for coronary heart disease (CHD) and all-cause mortality (ACM), independent of a wide range of potential confounders.2

Type D personality (TDP: D stands for ‘distressed') has been identified as a risk factor for negative health outcomes in CHD patients, including impaired health status, emotional distress, higher macrophage superoxide anion production, and cardiovascular morbidity and mortality.3,4 TDP refers to simultaneously high levels of negative affectivity (NA), the tendency to experience negative emotions, and social inhibition (SI), the tendency to inhibit self-expression in social interactions.3 Suggestions have been made for routine screening of TDP for identifying patients at risk of CHD.5 Associations between TDP and mortality have been presented for several cardiovascular patient groups,610 but other studies have shown no effect of TDP.1012 Moreover, there is ambiguity regarding the appropriate method to measure TDP, using dichotomised NA ≥ 10 and SI ≥ 10,3 NA and SI as indices,1315 the interaction term NA × SI,14 or their z-scores zNA × zSI.14,16  Table 1 gives an overview of previous research.

Table 1.

Studies assessing the prognostic value of the type D personality regarding cardiac events and mortality.

StudyMethods
Type D assessment
Prevalence of type D personalityEffect size (CI)
Design (SD)Sample n, mean age (SD) (% male)MeasureSettingsOutcomes
Denollet et al., 19966Prospective 6–10-year study303 CAD patients, 55.4 (7.9) (88%)DS14 dicRehabilitation programmeACM28%OR 4.1 (1.9–8.8)
Denollet et al., 200017Prospective 5-year study319 CAD patients, 56.7 (92%)DS16 dicRehabilitation programmeCardiac events31%OR 4.7 (2.2–7.8)
Pedersen et al., 200418Prospective 9-months study875 PCI patients, 62.2 (10.9) (72%)DS14 dic6 Months after PCICardiac events29%OR 5.38 (2.06–13.66)
Denollet et al., 200619Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeCardiac eventsOR 4.84 (1.42–16.52)
Denollet et al., 200620Prospective 9- months study875 CHD patients, 62.2 (75%)DS14 dicRehabilitation programmeMACEHR 1.92 (1.22–3.01)
Denollet et al., 200821Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeMACE29%OR 2.44 (1.25–4.76)
Denollet et al., 20078Prospective 5.4-years51 Heart transplant patients, 54.1 (9.7) (75%)DS14 dicBefore transplantationACM29%OR 6.75 (1.47–30.97)
Aquarius et al., 200922Prospective 4-year study184 Patients with peripheral arterial disease, 64.8 (9.8) (63.6%)DS14 dicBefore diagnosisACM35%OR 3.5 (1.11–11.1)
Martens et al., 201023Prospective 1.8 (0.8) years473 MI patients, 59 (12) (78%)DS14 dicHospitalisation for MICardiac events20%OR 2.23 (1.14–4.35)
Schiffer et al., 201024Prospective 30.7 (11.1) months232 CHF patients, 65.5 (9.9) (75%)DS14 dicConsecutive CHF outpatientsCardiac mortality20.7%OR 1.40 (0.93–4.29)
Pelle et al., 201010Prospective 37.6 (15.6) months641 CHF patients, 66.6 (10) (74%)DS14 dic2 Weeks after outpatient visitACM20%OR 1.16 (0.72–1.87)
Volz et al., 201112Prospective 2.8 (1.1) years111 CHF rehab patients, 57 (14) (88%)DS14 dicDuring rehabilitation programmeACM30%OR 1.40 (0.38–5.14)
Grande et al., 201125Prospective 71.5 (3.6) months977 CAD patients, 63.3 (10.7) (77.5%)NA, SI, NA × SIDifferent settingsACM25%HR NA × SI 0.99 (0.61–1.59), NA 1.01 (0.97–1.05), SI 1.03 (0.97–1.10)
Coyne et al., 201114Prospective 18 months706 CHF patients, 70.7 (11.5) (61.8%)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationACM13.5%HR 0.89 (0.58–1.37), zNA 0.87 (0.72–1.05), zSI 0.97 (0.83–1.02) zNA × zSI 0.9 (0.79–1.04)
Denollet et al., 20139Prospective 5-year study541 Patients with CAD, 58.7 (10.5) (87%)DS14 dic, zNA, zSI, zNA × zSIOutpatient rehabilitation programmeMACEOR 1.74 (1.11–2.73) zNA 0.99 (0.78–1.26), zSI 1.16 (0.92–1.47), zNA × zSI 1.36 (1.11–1.67)
Damen et al., 201326Prospective 7-year (1.6) follow-upConsecutive PCI patients, 62.0 (11.1) (72%)DS14 dic6 Months post-PCIACM29.2%HR 1.19 (0.76–1.85)
Denollet et al., 201327Prospective 3.2 years455 Patients with ICD, 59.1 (8.9)DS14 dicPrior to implantationACM23%HR 0 1.91 (1.09–3.34)
Meyer et al., 201428Prospective 5-year follow-up465 Consecutive patients with CAD, 62.0 (11.1) (72%)NA, SI and NA × SIBefore undergoing stent implantationMACE31%HR NA 1.02 (0.91–1.13), SI 0.86 (0.75–1.00), NA × SI 1.00 (0.99–1.01)
Dulfer et al., 201529Prospective 10-years follow-up1190 Consecutive patients who underwent PCI, 62 (73%)DS14 dic, zNA × zSI6 Months post-PCIACM25%HR 1.58 (1.22–2.03), zNA × zSI 1.24 (0.94–1.63)
Condén et al., 2016 (present study)Prospective 6.2 years (2.9) follow-up946 Consecutive patients with acute MI, 70 (11.7)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationRecurrent MI and ACM14%RMI: HR: 1.16 (0.76–1.77), zNA 1.03 (0.88–1.21), zSI 1.06 (0.90–1.24), zNA × zSI 1.03 (0.90–1.18) ACM: HR: 0.94 (0.68–1.31), zNA 1.03 (0.92–1.15), zSI 1.14 (1.02–1.27), zNA × zSI 1.00 (0.90–1.11)
StudyMethods
Type D assessment
Prevalence of type D personalityEffect size (CI)
Design (SD)Sample n, mean age (SD) (% male)MeasureSettingsOutcomes
Denollet et al., 19966Prospective 6–10-year study303 CAD patients, 55.4 (7.9) (88%)DS14 dicRehabilitation programmeACM28%OR 4.1 (1.9–8.8)
Denollet et al., 200017Prospective 5-year study319 CAD patients, 56.7 (92%)DS16 dicRehabilitation programmeCardiac events31%OR 4.7 (2.2–7.8)
Pedersen et al., 200418Prospective 9-months study875 PCI patients, 62.2 (10.9) (72%)DS14 dic6 Months after PCICardiac events29%OR 5.38 (2.06–13.66)
Denollet et al., 200619Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeCardiac eventsOR 4.84 (1.42–16.52)
Denollet et al., 200620Prospective 9- months study875 CHD patients, 62.2 (75%)DS14 dicRehabilitation programmeMACEHR 1.92 (1.22–3.01)
Denollet et al., 200821Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeMACE29%OR 2.44 (1.25–4.76)
Denollet et al., 20078Prospective 5.4-years51 Heart transplant patients, 54.1 (9.7) (75%)DS14 dicBefore transplantationACM29%OR 6.75 (1.47–30.97)
Aquarius et al., 200922Prospective 4-year study184 Patients with peripheral arterial disease, 64.8 (9.8) (63.6%)DS14 dicBefore diagnosisACM35%OR 3.5 (1.11–11.1)
Martens et al., 201023Prospective 1.8 (0.8) years473 MI patients, 59 (12) (78%)DS14 dicHospitalisation for MICardiac events20%OR 2.23 (1.14–4.35)
Schiffer et al., 201024Prospective 30.7 (11.1) months232 CHF patients, 65.5 (9.9) (75%)DS14 dicConsecutive CHF outpatientsCardiac mortality20.7%OR 1.40 (0.93–4.29)
Pelle et al., 201010Prospective 37.6 (15.6) months641 CHF patients, 66.6 (10) (74%)DS14 dic2 Weeks after outpatient visitACM20%OR 1.16 (0.72–1.87)
Volz et al., 201112Prospective 2.8 (1.1) years111 CHF rehab patients, 57 (14) (88%)DS14 dicDuring rehabilitation programmeACM30%OR 1.40 (0.38–5.14)
Grande et al., 201125Prospective 71.5 (3.6) months977 CAD patients, 63.3 (10.7) (77.5%)NA, SI, NA × SIDifferent settingsACM25%HR NA × SI 0.99 (0.61–1.59), NA 1.01 (0.97–1.05), SI 1.03 (0.97–1.10)
Coyne et al., 201114Prospective 18 months706 CHF patients, 70.7 (11.5) (61.8%)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationACM13.5%HR 0.89 (0.58–1.37), zNA 0.87 (0.72–1.05), zSI 0.97 (0.83–1.02) zNA × zSI 0.9 (0.79–1.04)
Denollet et al., 20139Prospective 5-year study541 Patients with CAD, 58.7 (10.5) (87%)DS14 dic, zNA, zSI, zNA × zSIOutpatient rehabilitation programmeMACEOR 1.74 (1.11–2.73) zNA 0.99 (0.78–1.26), zSI 1.16 (0.92–1.47), zNA × zSI 1.36 (1.11–1.67)
Damen et al., 201326Prospective 7-year (1.6) follow-upConsecutive PCI patients, 62.0 (11.1) (72%)DS14 dic6 Months post-PCIACM29.2%HR 1.19 (0.76–1.85)
Denollet et al., 201327Prospective 3.2 years455 Patients with ICD, 59.1 (8.9)DS14 dicPrior to implantationACM23%HR 0 1.91 (1.09–3.34)
Meyer et al., 201428Prospective 5-year follow-up465 Consecutive patients with CAD, 62.0 (11.1) (72%)NA, SI and NA × SIBefore undergoing stent implantationMACE31%HR NA 1.02 (0.91–1.13), SI 0.86 (0.75–1.00), NA × SI 1.00 (0.99–1.01)
Dulfer et al., 201529Prospective 10-years follow-up1190 Consecutive patients who underwent PCI, 62 (73%)DS14 dic, zNA × zSI6 Months post-PCIACM25%HR 1.58 (1.22–2.03), zNA × zSI 1.24 (0.94–1.63)
Condén et al., 2016 (present study)Prospective 6.2 years (2.9) follow-up946 Consecutive patients with acute MI, 70 (11.7)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationRecurrent MI and ACM14%RMI: HR: 1.16 (0.76–1.77), zNA 1.03 (0.88–1.21), zSI 1.06 (0.90–1.24), zNA × zSI 1.03 (0.90–1.18) ACM: HR: 0.94 (0.68–1.31), zNA 1.03 (0.92–1.15), zSI 1.14 (1.02–1.27), zNA × zSI 1.00 (0.90–1.11)

ACM: all-cause mortality; CAD: coronary artery disease; CHF: chronic heart failure; CI: confidence interval; dic: dichotomous; HR: hazard ratio; ICD: implantable cardioverter defibrillator; MACE: major adverse cardiac event; MI: myocardial infarction; NA: negative affectivity; OR: odds ratio; PCI: percutaneous coronary intervention; QoL: quality of life; RMI: recurrent MI; SI: social inhibition.

Table 1.

Studies assessing the prognostic value of the type D personality regarding cardiac events and mortality.

StudyMethods
Type D assessment
Prevalence of type D personalityEffect size (CI)
Design (SD)Sample n, mean age (SD) (% male)MeasureSettingsOutcomes
Denollet et al., 19966Prospective 6–10-year study303 CAD patients, 55.4 (7.9) (88%)DS14 dicRehabilitation programmeACM28%OR 4.1 (1.9–8.8)
Denollet et al., 200017Prospective 5-year study319 CAD patients, 56.7 (92%)DS16 dicRehabilitation programmeCardiac events31%OR 4.7 (2.2–7.8)
Pedersen et al., 200418Prospective 9-months study875 PCI patients, 62.2 (10.9) (72%)DS14 dic6 Months after PCICardiac events29%OR 5.38 (2.06–13.66)
Denollet et al., 200619Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeCardiac eventsOR 4.84 (1.42–16.52)
Denollet et al., 200620Prospective 9- months study875 CHD patients, 62.2 (75%)DS14 dicRehabilitation programmeMACEHR 1.92 (1.22–3.01)
Denollet et al., 200821Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeMACE29%OR 2.44 (1.25–4.76)
Denollet et al., 20078Prospective 5.4-years51 Heart transplant patients, 54.1 (9.7) (75%)DS14 dicBefore transplantationACM29%OR 6.75 (1.47–30.97)
Aquarius et al., 200922Prospective 4-year study184 Patients with peripheral arterial disease, 64.8 (9.8) (63.6%)DS14 dicBefore diagnosisACM35%OR 3.5 (1.11–11.1)
Martens et al., 201023Prospective 1.8 (0.8) years473 MI patients, 59 (12) (78%)DS14 dicHospitalisation for MICardiac events20%OR 2.23 (1.14–4.35)
Schiffer et al., 201024Prospective 30.7 (11.1) months232 CHF patients, 65.5 (9.9) (75%)DS14 dicConsecutive CHF outpatientsCardiac mortality20.7%OR 1.40 (0.93–4.29)
Pelle et al., 201010Prospective 37.6 (15.6) months641 CHF patients, 66.6 (10) (74%)DS14 dic2 Weeks after outpatient visitACM20%OR 1.16 (0.72–1.87)
Volz et al., 201112Prospective 2.8 (1.1) years111 CHF rehab patients, 57 (14) (88%)DS14 dicDuring rehabilitation programmeACM30%OR 1.40 (0.38–5.14)
Grande et al., 201125Prospective 71.5 (3.6) months977 CAD patients, 63.3 (10.7) (77.5%)NA, SI, NA × SIDifferent settingsACM25%HR NA × SI 0.99 (0.61–1.59), NA 1.01 (0.97–1.05), SI 1.03 (0.97–1.10)
Coyne et al., 201114Prospective 18 months706 CHF patients, 70.7 (11.5) (61.8%)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationACM13.5%HR 0.89 (0.58–1.37), zNA 0.87 (0.72–1.05), zSI 0.97 (0.83–1.02) zNA × zSI 0.9 (0.79–1.04)
Denollet et al., 20139Prospective 5-year study541 Patients with CAD, 58.7 (10.5) (87%)DS14 dic, zNA, zSI, zNA × zSIOutpatient rehabilitation programmeMACEOR 1.74 (1.11–2.73) zNA 0.99 (0.78–1.26), zSI 1.16 (0.92–1.47), zNA × zSI 1.36 (1.11–1.67)
Damen et al., 201326Prospective 7-year (1.6) follow-upConsecutive PCI patients, 62.0 (11.1) (72%)DS14 dic6 Months post-PCIACM29.2%HR 1.19 (0.76–1.85)
Denollet et al., 201327Prospective 3.2 years455 Patients with ICD, 59.1 (8.9)DS14 dicPrior to implantationACM23%HR 0 1.91 (1.09–3.34)
Meyer et al., 201428Prospective 5-year follow-up465 Consecutive patients with CAD, 62.0 (11.1) (72%)NA, SI and NA × SIBefore undergoing stent implantationMACE31%HR NA 1.02 (0.91–1.13), SI 0.86 (0.75–1.00), NA × SI 1.00 (0.99–1.01)
Dulfer et al., 201529Prospective 10-years follow-up1190 Consecutive patients who underwent PCI, 62 (73%)DS14 dic, zNA × zSI6 Months post-PCIACM25%HR 1.58 (1.22–2.03), zNA × zSI 1.24 (0.94–1.63)
Condén et al., 2016 (present study)Prospective 6.2 years (2.9) follow-up946 Consecutive patients with acute MI, 70 (11.7)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationRecurrent MI and ACM14%RMI: HR: 1.16 (0.76–1.77), zNA 1.03 (0.88–1.21), zSI 1.06 (0.90–1.24), zNA × zSI 1.03 (0.90–1.18) ACM: HR: 0.94 (0.68–1.31), zNA 1.03 (0.92–1.15), zSI 1.14 (1.02–1.27), zNA × zSI 1.00 (0.90–1.11)
StudyMethods
Type D assessment
Prevalence of type D personalityEffect size (CI)
Design (SD)Sample n, mean age (SD) (% male)MeasureSettingsOutcomes
Denollet et al., 19966Prospective 6–10-year study303 CAD patients, 55.4 (7.9) (88%)DS14 dicRehabilitation programmeACM28%OR 4.1 (1.9–8.8)
Denollet et al., 200017Prospective 5-year study319 CAD patients, 56.7 (92%)DS16 dicRehabilitation programmeCardiac events31%OR 4.7 (2.2–7.8)
Pedersen et al., 200418Prospective 9-months study875 PCI patients, 62.2 (10.9) (72%)DS14 dic6 Months after PCICardiac events29%OR 5.38 (2.06–13.66)
Denollet et al., 200619Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeCardiac eventsOR 4.84 (1.42–16.52)
Denollet et al., 200620Prospective 9- months study875 CHD patients, 62.2 (75%)DS14 dicRehabilitation programmeMACEHR 1.92 (1.22–3.01)
Denollet et al., 200821Prospective 5-year study337 CHD patients, 57.0 (88%)DS16Rehabilitation programmeMACE29%OR 2.44 (1.25–4.76)
Denollet et al., 20078Prospective 5.4-years51 Heart transplant patients, 54.1 (9.7) (75%)DS14 dicBefore transplantationACM29%OR 6.75 (1.47–30.97)
Aquarius et al., 200922Prospective 4-year study184 Patients with peripheral arterial disease, 64.8 (9.8) (63.6%)DS14 dicBefore diagnosisACM35%OR 3.5 (1.11–11.1)
Martens et al., 201023Prospective 1.8 (0.8) years473 MI patients, 59 (12) (78%)DS14 dicHospitalisation for MICardiac events20%OR 2.23 (1.14–4.35)
Schiffer et al., 201024Prospective 30.7 (11.1) months232 CHF patients, 65.5 (9.9) (75%)DS14 dicConsecutive CHF outpatientsCardiac mortality20.7%OR 1.40 (0.93–4.29)
Pelle et al., 201010Prospective 37.6 (15.6) months641 CHF patients, 66.6 (10) (74%)DS14 dic2 Weeks after outpatient visitACM20%OR 1.16 (0.72–1.87)
Volz et al., 201112Prospective 2.8 (1.1) years111 CHF rehab patients, 57 (14) (88%)DS14 dicDuring rehabilitation programmeACM30%OR 1.40 (0.38–5.14)
Grande et al., 201125Prospective 71.5 (3.6) months977 CAD patients, 63.3 (10.7) (77.5%)NA, SI, NA × SIDifferent settingsACM25%HR NA × SI 0.99 (0.61–1.59), NA 1.01 (0.97–1.05), SI 1.03 (0.97–1.10)
Coyne et al., 201114Prospective 18 months706 CHF patients, 70.7 (11.5) (61.8%)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationACM13.5%HR 0.89 (0.58–1.37), zNA 0.87 (0.72–1.05), zSI 0.97 (0.83–1.02) zNA × zSI 0.9 (0.79–1.04)
Denollet et al., 20139Prospective 5-year study541 Patients with CAD, 58.7 (10.5) (87%)DS14 dic, zNA, zSI, zNA × zSIOutpatient rehabilitation programmeMACEOR 1.74 (1.11–2.73) zNA 0.99 (0.78–1.26), zSI 1.16 (0.92–1.47), zNA × zSI 1.36 (1.11–1.67)
Damen et al., 201326Prospective 7-year (1.6) follow-upConsecutive PCI patients, 62.0 (11.1) (72%)DS14 dic6 Months post-PCIACM29.2%HR 1.19 (0.76–1.85)
Denollet et al., 201327Prospective 3.2 years455 Patients with ICD, 59.1 (8.9)DS14 dicPrior to implantationACM23%HR 0 1.91 (1.09–3.34)
Meyer et al., 201428Prospective 5-year follow-up465 Consecutive patients with CAD, 62.0 (11.1) (72%)NA, SI and NA × SIBefore undergoing stent implantationMACE31%HR NA 1.02 (0.91–1.13), SI 0.86 (0.75–1.00), NA × SI 1.00 (0.99–1.01)
Dulfer et al., 201529Prospective 10-years follow-up1190 Consecutive patients who underwent PCI, 62 (73%)DS14 dic, zNA × zSI6 Months post-PCIACM25%HR 1.58 (1.22–2.03), zNA × zSI 1.24 (0.94–1.63)
Condén et al., 2016 (present study)Prospective 6.2 years (2.9) follow-up946 Consecutive patients with acute MI, 70 (11.7)DS14 dic, zNA, zSI, zNA × zSIDuring hospitalisationRecurrent MI and ACM14%RMI: HR: 1.16 (0.76–1.77), zNA 1.03 (0.88–1.21), zSI 1.06 (0.90–1.24), zNA × zSI 1.03 (0.90–1.18) ACM: HR: 0.94 (0.68–1.31), zNA 1.03 (0.92–1.15), zSI 1.14 (1.02–1.27), zNA × zSI 1.00 (0.90–1.11)

ACM: all-cause mortality; CAD: coronary artery disease; CHF: chronic heart failure; CI: confidence interval; dic: dichotomous; HR: hazard ratio; ICD: implantable cardioverter defibrillator; MACE: major adverse cardiac event; MI: myocardial infarction; NA: negative affectivity; OR: odds ratio; PCI: percutaneous coronary intervention; QoL: quality of life; RMI: recurrent MI; SI: social inhibition.

Aim

The aim of this study was to examine whether TDP is independently associated with recurrent myocardial infarction (RMI) or ACM in post-acute myocardial infarction (MI) patients, using any of the previously proposed methods for measuring TDP.

Methods

The present study used data from the Västmanland Myocardial Infarction Study (VaMIS; ClinicalTrials.gov: NCT-01452178). The Uppsala Regional Ethical Review Board approved the study (DNR: 2005:169).

Patients and procedures

The VaMIS study included patients aged ≥18 years old with acute myocardial infarction (AMI) admitted to the Central Hospital, Västerås, Sweden, from November 2005–May 2011. AMI was diagnosed using ECG and biomarker criteria from the European Society of Cardiology: a rise in serum concentration of troponin-I to ≥0.4 µg/l and a subsequent fall, in combination with: (a) ischaemic symptoms; (b) development of Q waves on the ECG; (c) ECG changes indicative of ischaemia (ST segment elevation or depression); or (d) coronary artery intervention.30 Exclusion criteria included: not residing in the hospital’s catchment area, previous enrolment in VaMIS, inability to provide informed consent, language difficulties, and other severe disease, e.g. advanced cancer or cardiogenic shock. The intention was to include 1000 patients. In the end, 1008 patients were included, with 946 (93.8%) fulfilling the criteria for the present study of having no missing data on the DS14 instrument used to measure TDP (Figure 1).

Flowchart of study population. VaMIS: Västmanland Myocardial Infarction Study.
Figure 1.

Flowchart of study population. VaMIS: Västmanland Myocardial Infarction Study.

After giving written informed consent, the participants answered questions regarding the DS14 instrument and sociodemographic, lifestyle, and clinical risk factors. Clinical and anthropometric variables were measured and blood samples were collected by venepuncture in the morning four days after entering the hospital, if possible in a fasting state.

Primary outcome

The primary outcome was the occurrence of RMI or ACM, respectively, during follow-up until 9 December 2015, extracted from the Swedish national heart disease register (SWEDEHEART), and the Swedish population register, respectively. Time-to-event was calculated as the time from date of inclusion in the study until date of occurrence of the event of interest (either RMI or death) or censoring (date of emigration from Sweden or 9 December 2015).

Risk factors

TDP

TDP, the risk factor of main interest, was assessed using the DS14 instrument. It consists of two seven-item subscales, NA and SI, with responses given on a five-point Likert scale ranging from zero (‘false’) to four (‘true’), resulting in a total score of 0–28 for each subscale. TDP is defined as simultaneously scoring NA ≥ 10 and SI ≥ 10. It has, however, been suggested that TDP should instead be measured using NA and SI as indices,1315 their interaction term (NA × SI),14 or their normalised z-scores zNA and zSI,14,16 all of which will be evaluated in the present study. A Swedish version of the DS14 instrument was used that has been validated in a Swedish cardiac patient sample,31 giving internal consistencies of α = 0.80 and α = 0.78 for the NA and SI items, respectively.

Secondary risk factors

Besides TDP, the present study included risk factors sex, age, smoking, diabetes, hypertension treatment, systolic blood pressure (SBP), total cholesterol, and high-density lipoprotein (HDL). Additionally, the sociodemographic variables of immigrant (yes/no), living alone (yes/no), and highest education level (elementary school or no formal education/secondary school/college or university) were included as risk factors, together with physical activity during leisure time (low/mild/moderate or strenuous) and body mass index (BMI). Finally, the clinical variables prior MI (yes/no), percutaneous coronary intervention (PCI) during index hospitalisation (yes/no), heart rate (bpm), creatinine (µmol/l), C-reactive protein (CRP) (mg/l), N-terminal pro b-type natriuretic peptide (NT-proBNP) (ng/l), and use of β-blockers (yes/no) or diuretics (yes/no) at discharge, were included.

Statistical analyses

Descriptive statistics are presented as frequencies and percentages, n (%), for categorical data, while means and standard deviations (SDs) are used for ordinal and continuous data. Differences between two groups are analysed using Pearson’s χ2-test for categorical data and the Mann-Whitney test for ordinal and continuous data.

Cox regression was used to examine the association between risk factors and outcomes. The DS14 instrument was included in the regression models in various forms: (a) as a single variable obtained by dichotomising the DS14 instrument, i.e. NA ≥ 10 and SI ≥ 10 (yes/no), NA ≥ 10 (yes/no), or SI ≥ 10 (yes/no), the index variables NA (score 0–28), SI (score 0–28), zNA, or zSI, or the index interactions NA × SI or zNA × zSI; (b) as multiple variables including both subscales NA and SI in dichotomised or index form, with or without interaction. The regression analyses were performed in four steps: In the first three steps, complete cases analyses were used for constructing basic models, estimated separately for the various forms of DS14 as well as the secondary risk factors; reduced models, where the DS14 were adjusted for the secondary risk factors with p-values<0.20 in the basic models; and full models, where the DS14 were adjusted for all secondary risk factors. In the final step, a fully conditional specification imputation method was used to construct a multiple imputation data set, for which a full model was applied. The fully conditional specification used 10 imputations, with zNA × zSI, and all secondary risk factors included in the imputation model. The regression analyses are reported as hazard ratios (HRs) with 95% confidence intervals (CIs), with pooled estimates used for the multiple imputation data set. Statistical analyses were performed in IBM SPSS Statistics 23/24, with two-sided p-values<0.05 considered statistically significant.

Results

Descriptive data are given in Table 2, while Tables 3 and 4 give results for the basic and multiple regression models, respectively. Most of the 946 included patients were men (n = 632; 66.8%). The mean (SD) age was 70.4 (11.7; range 38.3–97.1) years, with 133 (14.1%) having TDP (NA ≥ 10 and SI ≥ 10. Compared to those excluded, the included patients were less often undergoing hypertension treatment, had a higher education level, were more physical active during leisure time, and had less often suffered from a prior MI (data not shown).

Table 2.

Descriptive data for the study population.

Type of variableVariableValueValid, n (%)
OutcomeRecurrent MI, n (%)166 (17.5)946 (100.0)
All-cause mortality, n (%)321 (33.9)946 (100.0)
DS-14NA (score 0–28), mean (SD)6.6 (5.5)946 (100.0)
SI (score 0–28), mean (SD)7.9 (5.8)946 (100.0)
Type D personality (NA ≥ 10 and SI ≥ 10), n (%)133 (14.1)946 (100.0)
CVD risk factorsMale sex, n (%)632 (66.8)946 (100.0)
Age (years), mean (SD)70.4 (11.9)946 (100.0)
Smoker, n (%)184 (19.5)945 (99.9)
Diabetes, n (%)170 (18.0)946 (100.0)
Hypertension treatment, n (%)471 (49.8)946 (100.0)
SBP (mm Hg), mean (SD)126.6 (20.9)930 (98.3)
Total cholesterol (mg/dl), mean (SD)a188.7 (50.5)845 (89.3)
HDL cholesterol (mg/dl), mean (SD)a43.4 (14.2)845 (89.3)
Sociodemographic factorsImmigrant, n (%)175 (18.5)946 (100.0)
Living alone, n (%)325 (34.4)946 (100.0)
Highest education level, n (%)941 (99.5)
Elementary school or no formal education479 (50.9)
Secondary school314 (33.4)
College or university148 (15.7)
Lifestyle factorsPhysical activity during leisure time, n (%)930 (98.3)
Low399 (42.9)
Mild291 (31.3)
Moderate or strenuous240 (25.8)
Body mass index (kg/m2), mean (SD)27.0 (4.8)937 (99.0)
Clinical factorsPrior MI, n (%)222 (23.5)946 (100.0)
PCI during index hospitalisation, n (%)476 (50.3)946 (100.0)
Heart rate (bpm), mean (SD)68.1 (11.9)904 (95.6)
Creatinine (µmol/l), mean (SD)96.5 (55.6)942 (99.6)
CRP (mg/l), mean (SD)17.4 (38.4)910 (96.2)
NT-proBNP (ng/l), mean (SD)4.5 (8.5)942 (99.6)
β-blockers, n (%)860 (93.0)925 (97.8)
Diuretics, n (%)205 (22.1)926 (97.9)
Type of variableVariableValueValid, n (%)
OutcomeRecurrent MI, n (%)166 (17.5)946 (100.0)
All-cause mortality, n (%)321 (33.9)946 (100.0)
DS-14NA (score 0–28), mean (SD)6.6 (5.5)946 (100.0)
SI (score 0–28), mean (SD)7.9 (5.8)946 (100.0)
Type D personality (NA ≥ 10 and SI ≥ 10), n (%)133 (14.1)946 (100.0)
CVD risk factorsMale sex, n (%)632 (66.8)946 (100.0)
Age (years), mean (SD)70.4 (11.9)946 (100.0)
Smoker, n (%)184 (19.5)945 (99.9)
Diabetes, n (%)170 (18.0)946 (100.0)
Hypertension treatment, n (%)471 (49.8)946 (100.0)
SBP (mm Hg), mean (SD)126.6 (20.9)930 (98.3)
Total cholesterol (mg/dl), mean (SD)a188.7 (50.5)845 (89.3)
HDL cholesterol (mg/dl), mean (SD)a43.4 (14.2)845 (89.3)
Sociodemographic factorsImmigrant, n (%)175 (18.5)946 (100.0)
Living alone, n (%)325 (34.4)946 (100.0)
Highest education level, n (%)941 (99.5)
Elementary school or no formal education479 (50.9)
Secondary school314 (33.4)
College or university148 (15.7)
Lifestyle factorsPhysical activity during leisure time, n (%)930 (98.3)
Low399 (42.9)
Mild291 (31.3)
Moderate or strenuous240 (25.8)
Body mass index (kg/m2), mean (SD)27.0 (4.8)937 (99.0)
Clinical factorsPrior MI, n (%)222 (23.5)946 (100.0)
PCI during index hospitalisation, n (%)476 (50.3)946 (100.0)
Heart rate (bpm), mean (SD)68.1 (11.9)904 (95.6)
Creatinine (µmol/l), mean (SD)96.5 (55.6)942 (99.6)
CRP (mg/l), mean (SD)17.4 (38.4)910 (96.2)
NT-proBNP (ng/l), mean (SD)4.5 (8.5)942 (99.6)
β-blockers, n (%)860 (93.0)925 (97.8)
Diuretics, n (%)205 (22.1)926 (97.9)

CRP: C-reactive protein; CVD: cardiovascular disease; HDL: high density lipoprotein; MI: myocardial infarction; NA: negative affectivity; NT-proBNP: N-terminal pro b-type natriuretic peptide; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; SD: standard deviation; SI: social inhibition.

a

Converted from mmol/l using the conversion factor 38.6598.

Table 2.

Descriptive data for the study population.

Type of variableVariableValueValid, n (%)
OutcomeRecurrent MI, n (%)166 (17.5)946 (100.0)
All-cause mortality, n (%)321 (33.9)946 (100.0)
DS-14NA (score 0–28), mean (SD)6.6 (5.5)946 (100.0)
SI (score 0–28), mean (SD)7.9 (5.8)946 (100.0)
Type D personality (NA ≥ 10 and SI ≥ 10), n (%)133 (14.1)946 (100.0)
CVD risk factorsMale sex, n (%)632 (66.8)946 (100.0)
Age (years), mean (SD)70.4 (11.9)946 (100.0)
Smoker, n (%)184 (19.5)945 (99.9)
Diabetes, n (%)170 (18.0)946 (100.0)
Hypertension treatment, n (%)471 (49.8)946 (100.0)
SBP (mm Hg), mean (SD)126.6 (20.9)930 (98.3)
Total cholesterol (mg/dl), mean (SD)a188.7 (50.5)845 (89.3)
HDL cholesterol (mg/dl), mean (SD)a43.4 (14.2)845 (89.3)
Sociodemographic factorsImmigrant, n (%)175 (18.5)946 (100.0)
Living alone, n (%)325 (34.4)946 (100.0)
Highest education level, n (%)941 (99.5)
Elementary school or no formal education479 (50.9)
Secondary school314 (33.4)
College or university148 (15.7)
Lifestyle factorsPhysical activity during leisure time, n (%)930 (98.3)
Low399 (42.9)
Mild291 (31.3)
Moderate or strenuous240 (25.8)
Body mass index (kg/m2), mean (SD)27.0 (4.8)937 (99.0)
Clinical factorsPrior MI, n (%)222 (23.5)946 (100.0)
PCI during index hospitalisation, n (%)476 (50.3)946 (100.0)
Heart rate (bpm), mean (SD)68.1 (11.9)904 (95.6)
Creatinine (µmol/l), mean (SD)96.5 (55.6)942 (99.6)
CRP (mg/l), mean (SD)17.4 (38.4)910 (96.2)
NT-proBNP (ng/l), mean (SD)4.5 (8.5)942 (99.6)
β-blockers, n (%)860 (93.0)925 (97.8)
Diuretics, n (%)205 (22.1)926 (97.9)
Type of variableVariableValueValid, n (%)
OutcomeRecurrent MI, n (%)166 (17.5)946 (100.0)
All-cause mortality, n (%)321 (33.9)946 (100.0)
DS-14NA (score 0–28), mean (SD)6.6 (5.5)946 (100.0)
SI (score 0–28), mean (SD)7.9 (5.8)946 (100.0)
Type D personality (NA ≥ 10 and SI ≥ 10), n (%)133 (14.1)946 (100.0)
CVD risk factorsMale sex, n (%)632 (66.8)946 (100.0)
Age (years), mean (SD)70.4 (11.9)946 (100.0)
Smoker, n (%)184 (19.5)945 (99.9)
Diabetes, n (%)170 (18.0)946 (100.0)
Hypertension treatment, n (%)471 (49.8)946 (100.0)
SBP (mm Hg), mean (SD)126.6 (20.9)930 (98.3)
Total cholesterol (mg/dl), mean (SD)a188.7 (50.5)845 (89.3)
HDL cholesterol (mg/dl), mean (SD)a43.4 (14.2)845 (89.3)
Sociodemographic factorsImmigrant, n (%)175 (18.5)946 (100.0)
Living alone, n (%)325 (34.4)946 (100.0)
Highest education level, n (%)941 (99.5)
Elementary school or no formal education479 (50.9)
Secondary school314 (33.4)
College or university148 (15.7)
Lifestyle factorsPhysical activity during leisure time, n (%)930 (98.3)
Low399 (42.9)
Mild291 (31.3)
Moderate or strenuous240 (25.8)
Body mass index (kg/m2), mean (SD)27.0 (4.8)937 (99.0)
Clinical factorsPrior MI, n (%)222 (23.5)946 (100.0)
PCI during index hospitalisation, n (%)476 (50.3)946 (100.0)
Heart rate (bpm), mean (SD)68.1 (11.9)904 (95.6)
Creatinine (µmol/l), mean (SD)96.5 (55.6)942 (99.6)
CRP (mg/l), mean (SD)17.4 (38.4)910 (96.2)
NT-proBNP (ng/l), mean (SD)4.5 (8.5)942 (99.6)
β-blockers, n (%)860 (93.0)925 (97.8)
Diuretics, n (%)205 (22.1)926 (97.9)

CRP: C-reactive protein; CVD: cardiovascular disease; HDL: high density lipoprotein; MI: myocardial infarction; NA: negative affectivity; NT-proBNP: N-terminal pro b-type natriuretic peptide; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; SD: standard deviation; SI: social inhibition.

a

Converted from mmol/l using the conversion factor 38.6598.

Table 3.

Basic Cox regression models for the outcomes recurrent myocardial infarction (MI) and all-cause mortality, respectively. Significant results are given in bold.

Recurrent MIAll-cause mortality
Type of variableVariableHR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)a1.16 (0.76–1.77)0.94 (0.68–1.31)
NA ≥ 101.24 (0.89–1.72)b0.98 (0.76–1.26)
SI ≥ 101.11 (0.80–1.52)1.12 (0.89–1.41)
NA (score 0–28)1.01 (0.97–1.04)1.00 (0.98–1.03)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)b
zNA1.03 (0.88–1.21)1.03 (0.92–1.15)
zSI1.06 (0.90–1.24)1.14 (1.02–1.27)b
zNA × zSI1.03 (0.90–1.18)1.00 (0.90–1.11)
DS-14 as multiple variablesDichotomised
NA ≥ 101.23 (0.88–1.71)0.96 (0.74–1.23)
SI ≥ 101.07 (0.77–1.47)1.13 (0.89–1.42)
Dichotomised + interaction
NA ≥ 101.32 (0.85–2.04)1.08 (0.77–1.50)
SI ≥ 101.13 (0.76–1.69)1.22 (0.93–1.61)b
(NA ≥ 10) × (SI ≥ 10)a0.85 (0.43–1.65)0.76 (0.46–1.26)
Index
NA (score 0–28)1.00 (0.97–1.04)1.00 (0.97–1.02)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
Index + interaction
NA (score 0–28)1.00 (0.95–1.05)1.00 (0.96–1.05)
SI (score 0–28)1.01 (0.96–1.06)1.03 (0.99–1.07)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.02 (0.86–1.20)0.98 (0.87–1.10)
zSI1.05 (0.89–1.24)1.15 (1.02–1.29)b
Normalised index + interaction
zNA1.01 (0.85–1.20)0.98 (0.87–1.11)
zSI1.05 (0.88–1.25)1.15 (1.02–1.30)b
zNA × zSI1.01 (0.88–1.17)0.98 (0.88–1.09)
CVD risk factorsMale sex0.90 (0.65–1.25)0.68 (0.54–0.86)b
Age (years)1.03 (1.01–1.05)b1.10 (1.09–1.12)b
Smoker0.73 (0.48–1.10)b0.44 (0.30–0.63)b
Diabetes2.62 (1.88–3.65)b1.98 (1.54–2.54)b
Hypertension treatment1.64 (1.20–2.24)b1.45 (1.16–1.81)b
SBP (mm Hg)1.01 (1.00–1.02)b1.00 (0.99–1.01)
Total cholesterol (mg/dl)c0.99 (0.98–1.00)b0.99 (0.98–1.00)b
HDL cholesterol (mg/dl)c0.99 (0.98–1.01)1.00 (0.99–1.02)
Sociodemographic factorsImmigrant0.92 (0.61–1.37)0.87 (0.65–1.17)
Living alone1.28 (0.93–1.76)b2.34 (1.87–2.92)b
Highest education level
Elementary school or no formal education1.19 (0.76–1.86)2.03 (1.41–2.93)b
Secondary school0.97 (0.60–1.57)1.16 (0.77–1.73)
College or universityRef.Ref.
Lifestyle factorsPhysical activity during leisure time
Low2.07 (1.37–3.13)b4.88 (3.39–7.02)b
Mild1.30 (0.83–2.05)2.07 (1.38–3.11)b
Moderate or strenuousRef.Ref.
Body mass index (kg/m2)1.00 (0.96–1.03)0.93 (0.90–0.96)b
Clinical factorsPrior MI3.32 (2.43–4.52)b2.41 (1.91–3.03)b
PCI during index hospitalisation0.78 (0.57–1.06)b0.41 (0.32–0.52)b
Heart rate (bpm)1.02 (1.00–1.04)b1.03 (1.01–1.04)b
Creatinine (µmol/l)1.00 (1.00–1.01)b1.00 (1.00–1.01)b
CRP (mg/l)1.00 (0.99–1.01)1.01 (1.00–1.01)b
NT–proBNP (µg/l)1.02 (1.01–1.04)b1.04 (1.03–1.05)b
β-blockers1.11 (0.59–2.04)1.19 (0.74–1.90)
Diuretics2.30 (1.65–3.21)b4.30 (3.43–5.40)b
Recurrent MIAll-cause mortality
Type of variableVariableHR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)a1.16 (0.76–1.77)0.94 (0.68–1.31)
NA ≥ 101.24 (0.89–1.72)b0.98 (0.76–1.26)
SI ≥ 101.11 (0.80–1.52)1.12 (0.89–1.41)
NA (score 0–28)1.01 (0.97–1.04)1.00 (0.98–1.03)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)b
zNA1.03 (0.88–1.21)1.03 (0.92–1.15)
zSI1.06 (0.90–1.24)1.14 (1.02–1.27)b
zNA × zSI1.03 (0.90–1.18)1.00 (0.90–1.11)
DS-14 as multiple variablesDichotomised
NA ≥ 101.23 (0.88–1.71)0.96 (0.74–1.23)
SI ≥ 101.07 (0.77–1.47)1.13 (0.89–1.42)
Dichotomised + interaction
NA ≥ 101.32 (0.85–2.04)1.08 (0.77–1.50)
SI ≥ 101.13 (0.76–1.69)1.22 (0.93–1.61)b
(NA ≥ 10) × (SI ≥ 10)a0.85 (0.43–1.65)0.76 (0.46–1.26)
Index
NA (score 0–28)1.00 (0.97–1.04)1.00 (0.97–1.02)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
Index + interaction
NA (score 0–28)1.00 (0.95–1.05)1.00 (0.96–1.05)
SI (score 0–28)1.01 (0.96–1.06)1.03 (0.99–1.07)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.02 (0.86–1.20)0.98 (0.87–1.10)
zSI1.05 (0.89–1.24)1.15 (1.02–1.29)b
Normalised index + interaction
zNA1.01 (0.85–1.20)0.98 (0.87–1.11)
zSI1.05 (0.88–1.25)1.15 (1.02–1.30)b
zNA × zSI1.01 (0.88–1.17)0.98 (0.88–1.09)
CVD risk factorsMale sex0.90 (0.65–1.25)0.68 (0.54–0.86)b
Age (years)1.03 (1.01–1.05)b1.10 (1.09–1.12)b
Smoker0.73 (0.48–1.10)b0.44 (0.30–0.63)b
Diabetes2.62 (1.88–3.65)b1.98 (1.54–2.54)b
Hypertension treatment1.64 (1.20–2.24)b1.45 (1.16–1.81)b
SBP (mm Hg)1.01 (1.00–1.02)b1.00 (0.99–1.01)
Total cholesterol (mg/dl)c0.99 (0.98–1.00)b0.99 (0.98–1.00)b
HDL cholesterol (mg/dl)c0.99 (0.98–1.01)1.00 (0.99–1.02)
Sociodemographic factorsImmigrant0.92 (0.61–1.37)0.87 (0.65–1.17)
Living alone1.28 (0.93–1.76)b2.34 (1.87–2.92)b
Highest education level
Elementary school or no formal education1.19 (0.76–1.86)2.03 (1.41–2.93)b
Secondary school0.97 (0.60–1.57)1.16 (0.77–1.73)
College or universityRef.Ref.
Lifestyle factorsPhysical activity during leisure time
Low2.07 (1.37–3.13)b4.88 (3.39–7.02)b
Mild1.30 (0.83–2.05)2.07 (1.38–3.11)b
Moderate or strenuousRef.Ref.
Body mass index (kg/m2)1.00 (0.96–1.03)0.93 (0.90–0.96)b
Clinical factorsPrior MI3.32 (2.43–4.52)b2.41 (1.91–3.03)b
PCI during index hospitalisation0.78 (0.57–1.06)b0.41 (0.32–0.52)b
Heart rate (bpm)1.02 (1.00–1.04)b1.03 (1.01–1.04)b
Creatinine (µmol/l)1.00 (1.00–1.01)b1.00 (1.00–1.01)b
CRP (mg/l)1.00 (0.99–1.01)1.01 (1.00–1.01)b
NT–proBNP (µg/l)1.02 (1.01–1.04)b1.04 (1.03–1.05)b
β-blockers1.11 (0.59–2.04)1.19 (0.74–1.90)
Diuretics2.30 (1.65–3.21)b4.30 (3.43–5.40)b

CI: confidence interval; CRP: C-reactive protein; CVD: cardiovascular disease; HDL: high density lipoprotein; HR: hazard ratio; NA: negative affectivity; NT-proBNP: N-terminal pro b-type natriuretic peptide; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; SI: social inhibition.

a

NA ≥ 10 and SI ≥ 10 is equivalent to (NA ≥ 10) × (SI ≥ 10).

b

p-Value < 0.20.

c

Converted from mmol/l using the conversion factor 38.6598.

Table 3.

Basic Cox regression models for the outcomes recurrent myocardial infarction (MI) and all-cause mortality, respectively. Significant results are given in bold.

Recurrent MIAll-cause mortality
Type of variableVariableHR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)a1.16 (0.76–1.77)0.94 (0.68–1.31)
NA ≥ 101.24 (0.89–1.72)b0.98 (0.76–1.26)
SI ≥ 101.11 (0.80–1.52)1.12 (0.89–1.41)
NA (score 0–28)1.01 (0.97–1.04)1.00 (0.98–1.03)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)b
zNA1.03 (0.88–1.21)1.03 (0.92–1.15)
zSI1.06 (0.90–1.24)1.14 (1.02–1.27)b
zNA × zSI1.03 (0.90–1.18)1.00 (0.90–1.11)
DS-14 as multiple variablesDichotomised
NA ≥ 101.23 (0.88–1.71)0.96 (0.74–1.23)
SI ≥ 101.07 (0.77–1.47)1.13 (0.89–1.42)
Dichotomised + interaction
NA ≥ 101.32 (0.85–2.04)1.08 (0.77–1.50)
SI ≥ 101.13 (0.76–1.69)1.22 (0.93–1.61)b
(NA ≥ 10) × (SI ≥ 10)a0.85 (0.43–1.65)0.76 (0.46–1.26)
Index
NA (score 0–28)1.00 (0.97–1.04)1.00 (0.97–1.02)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
Index + interaction
NA (score 0–28)1.00 (0.95–1.05)1.00 (0.96–1.05)
SI (score 0–28)1.01 (0.96–1.06)1.03 (0.99–1.07)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.02 (0.86–1.20)0.98 (0.87–1.10)
zSI1.05 (0.89–1.24)1.15 (1.02–1.29)b
Normalised index + interaction
zNA1.01 (0.85–1.20)0.98 (0.87–1.11)
zSI1.05 (0.88–1.25)1.15 (1.02–1.30)b
zNA × zSI1.01 (0.88–1.17)0.98 (0.88–1.09)
CVD risk factorsMale sex0.90 (0.65–1.25)0.68 (0.54–0.86)b
Age (years)1.03 (1.01–1.05)b1.10 (1.09–1.12)b
Smoker0.73 (0.48–1.10)b0.44 (0.30–0.63)b
Diabetes2.62 (1.88–3.65)b1.98 (1.54–2.54)b
Hypertension treatment1.64 (1.20–2.24)b1.45 (1.16–1.81)b
SBP (mm Hg)1.01 (1.00–1.02)b1.00 (0.99–1.01)
Total cholesterol (mg/dl)c0.99 (0.98–1.00)b0.99 (0.98–1.00)b
HDL cholesterol (mg/dl)c0.99 (0.98–1.01)1.00 (0.99–1.02)
Sociodemographic factorsImmigrant0.92 (0.61–1.37)0.87 (0.65–1.17)
Living alone1.28 (0.93–1.76)b2.34 (1.87–2.92)b
Highest education level
Elementary school or no formal education1.19 (0.76–1.86)2.03 (1.41–2.93)b
Secondary school0.97 (0.60–1.57)1.16 (0.77–1.73)
College or universityRef.Ref.
Lifestyle factorsPhysical activity during leisure time
Low2.07 (1.37–3.13)b4.88 (3.39–7.02)b
Mild1.30 (0.83–2.05)2.07 (1.38–3.11)b
Moderate or strenuousRef.Ref.
Body mass index (kg/m2)1.00 (0.96–1.03)0.93 (0.90–0.96)b
Clinical factorsPrior MI3.32 (2.43–4.52)b2.41 (1.91–3.03)b
PCI during index hospitalisation0.78 (0.57–1.06)b0.41 (0.32–0.52)b
Heart rate (bpm)1.02 (1.00–1.04)b1.03 (1.01–1.04)b
Creatinine (µmol/l)1.00 (1.00–1.01)b1.00 (1.00–1.01)b
CRP (mg/l)1.00 (0.99–1.01)1.01 (1.00–1.01)b
NT–proBNP (µg/l)1.02 (1.01–1.04)b1.04 (1.03–1.05)b
β-blockers1.11 (0.59–2.04)1.19 (0.74–1.90)
Diuretics2.30 (1.65–3.21)b4.30 (3.43–5.40)b
Recurrent MIAll-cause mortality
Type of variableVariableHR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)a1.16 (0.76–1.77)0.94 (0.68–1.31)
NA ≥ 101.24 (0.89–1.72)b0.98 (0.76–1.26)
SI ≥ 101.11 (0.80–1.52)1.12 (0.89–1.41)
NA (score 0–28)1.01 (0.97–1.04)1.00 (0.98–1.03)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)b
zNA1.03 (0.88–1.21)1.03 (0.92–1.15)
zSI1.06 (0.90–1.24)1.14 (1.02–1.27)b
zNA × zSI1.03 (0.90–1.18)1.00 (0.90–1.11)
DS-14 as multiple variablesDichotomised
NA ≥ 101.23 (0.88–1.71)0.96 (0.74–1.23)
SI ≥ 101.07 (0.77–1.47)1.13 (0.89–1.42)
Dichotomised + interaction
NA ≥ 101.32 (0.85–2.04)1.08 (0.77–1.50)
SI ≥ 101.13 (0.76–1.69)1.22 (0.93–1.61)b
(NA ≥ 10) × (SI ≥ 10)a0.85 (0.43–1.65)0.76 (0.46–1.26)
Index
NA (score 0–28)1.00 (0.97–1.04)1.00 (0.97–1.02)
SI (score 0–28)1.01 (0.98–1.04)1.02 (1.00–1.05)b
Index + interaction
NA (score 0–28)1.00 (0.95–1.05)1.00 (0.96–1.05)
SI (score 0–28)1.01 (0.96–1.06)1.03 (0.99–1.07)b
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.02 (0.86–1.20)0.98 (0.87–1.10)
zSI1.05 (0.89–1.24)1.15 (1.02–1.29)b
Normalised index + interaction
zNA1.01 (0.85–1.20)0.98 (0.87–1.11)
zSI1.05 (0.88–1.25)1.15 (1.02–1.30)b
zNA × zSI1.01 (0.88–1.17)0.98 (0.88–1.09)
CVD risk factorsMale sex0.90 (0.65–1.25)0.68 (0.54–0.86)b
Age (years)1.03 (1.01–1.05)b1.10 (1.09–1.12)b
Smoker0.73 (0.48–1.10)b0.44 (0.30–0.63)b
Diabetes2.62 (1.88–3.65)b1.98 (1.54–2.54)b
Hypertension treatment1.64 (1.20–2.24)b1.45 (1.16–1.81)b
SBP (mm Hg)1.01 (1.00–1.02)b1.00 (0.99–1.01)
Total cholesterol (mg/dl)c0.99 (0.98–1.00)b0.99 (0.98–1.00)b
HDL cholesterol (mg/dl)c0.99 (0.98–1.01)1.00 (0.99–1.02)
Sociodemographic factorsImmigrant0.92 (0.61–1.37)0.87 (0.65–1.17)
Living alone1.28 (0.93–1.76)b2.34 (1.87–2.92)b
Highest education level
Elementary school or no formal education1.19 (0.76–1.86)2.03 (1.41–2.93)b
Secondary school0.97 (0.60–1.57)1.16 (0.77–1.73)
College or universityRef.Ref.
Lifestyle factorsPhysical activity during leisure time
Low2.07 (1.37–3.13)b4.88 (3.39–7.02)b
Mild1.30 (0.83–2.05)2.07 (1.38–3.11)b
Moderate or strenuousRef.Ref.
Body mass index (kg/m2)1.00 (0.96–1.03)0.93 (0.90–0.96)b
Clinical factorsPrior MI3.32 (2.43–4.52)b2.41 (1.91–3.03)b
PCI during index hospitalisation0.78 (0.57–1.06)b0.41 (0.32–0.52)b
Heart rate (bpm)1.02 (1.00–1.04)b1.03 (1.01–1.04)b
Creatinine (µmol/l)1.00 (1.00–1.01)b1.00 (1.00–1.01)b
CRP (mg/l)1.00 (0.99–1.01)1.01 (1.00–1.01)b
NT–proBNP (µg/l)1.02 (1.01–1.04)b1.04 (1.03–1.05)b
β-blockers1.11 (0.59–2.04)1.19 (0.74–1.90)
Diuretics2.30 (1.65–3.21)b4.30 (3.43–5.40)b

CI: confidence interval; CRP: C-reactive protein; CVD: cardiovascular disease; HDL: high density lipoprotein; HR: hazard ratio; NA: negative affectivity; NT-proBNP: N-terminal pro b-type natriuretic peptide; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; SI: social inhibition.

a

NA ≥ 10 and SI ≥ 10 is equivalent to (NA ≥ 10) × (SI ≥ 10).

b

p-Value < 0.20.

c

Converted from mmol/l using the conversion factor 38.6598.

Table 4.

Multiple Cox regression models for outcomes recurrent myocardial infarction (MI) and all-cause mortality, using complete cases and multiple imputed data analyses. Significant results are given in bold.

Complete cases analysis
Multiple imputed data analysis
Reduced modelaReduced modelbFull modelc,dFull modelc,dFull modelc,eFull modelc,e
Recurrent MIAll-cause mortalityRecurrent MIAll-cause mortalityRecurrent MIAll-cause mortality
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)f 1.17 (0.74–1.85) 1.02 (0.69–1.49) 1.27 (0.79–2.03) 0.99 (0.67–1.46) 1.07 (0.69–1.65) 0.97 (0.69–1.37)
NA ≥ 101.31 (0.91–1.89)1.18 (0.88–1.59)1.41 (0.97–2.04)1.15 (0.85–1.56)1.20 (0.86–1.69)1.12 (0.86–1.44)
SI ≥ 101.12 (0.79–1.59)0.82 (0.62–1.09)1.08 (0.74–1.57)0.81 (0.61–1.07)1.01 (0.72–1.41)0.86 (0.67–1.10)
NA (score 0–28)1.00 (0.97–1.04)1.01 (0.98–1.04)1.01 (0.97–1.04)1.01 (0.98–1.04)1.00 (0.97–1.03)1.01 (0.98–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.99 (0.96–1.01)1.01 (0.97–1.04)0.98 (0.95–1.01)1.00 (0.97–1.03)0.99 (0.97–1.02)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
zNA1.01 (0.85–1.20)1.07 (0.94–1.23)1.03 (0.86–1.23)1.06 (0.92–1.22)0.99 (0.84–1.16)1.05 (0.93–1.19)
zSI1.04 (0.87–1.23)0.92 (0.80–1.05)1.04 (0.86–1.25)0.90 (0.78–1.03)0.99 (0.84–1.17)0.96 (0.86–1.08)
zNA × zSI1.02 (0.88–1.18)1.01 (0.91–1.12)1.04 (0.90–1.21)1.00 (0.90–1.12)1.01 (0.88–1.16)0.98 (0.89–1.08)
DS-14 as multiple variablesDichotomised
NA ≥ 101.29 (0.89–1.87)1.24 (0.92–1.68)1.40 (0.96–2.05)1.22 (0.90–1.66)1.21 (0.86–1.71)1.15 (0.88–1.48)
SI ≥ 101.07 (0.75–1.53)0.79 (0.60–1.05)1.01 (0.69–1.49)0.78 (0.58–1.04)0.97 (0.69–1.37)0.84 (0.66–1.08)
Dichotomised + interaction
NA ≥ 101.46 (0.89–2.37)1.26 (0.84–1.89)1.48 (0.90–2.45)1.23 (0.81–1.85)1.31 (0.83–2.04)1.18 (0.84–1.66)
SI ≥ 101.18 (0.75–1.83)0.80 (0.57–1.11)1.06 (0.66–1.70)0.78 (0.55–1.09)1.04 (0.68–1.57)0.86 (0.64–1.15)
(NA ≥ 10) × (SI ≥ 10)f0.77 (0.37–1.59)0.98 (0.54–1.77)0.88 (0.41–1.87)0.99 (0.53–1.82)0.84 (0.42–1.66)0.93 (0.55–1.57)
Index
NA (score 0–28)1.00 (0.96–1.04)1.02 (0.99–1.06)1.00 (0.96–1.04)1.02 (0.99–1.05)1.00 (0.96–1.03)1.01 (0.99–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.98 (0.95–1.01)1.01 (0.97–1.04)0.97 (0.95–0.99)1.00 (0.96–1.03)0.99 (0.96–1.02)
Index + interaction
NA (score 0–28)1.00 (0.94–1.06)1.02 (0.97–1.07)0.99 (0.93–1.06)1.02 (0.97–1.07)0.99 (0.94–1.05)1.02 (0.98–1.07)
SI (score 0–28)1.00 (0.95–1.06)0.98 (0.93–1.02)1.00 (0.94–1.05)0.97 (0.93–1.02)1.00 (0.95–1.05)1.00 (0.96–1.03)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.00 (0.83–1.20)1.14 (0.98–1.32)1.02 (0.84–1.24)1.13 (0.97–1.31)0.99 (0.83–1.18)1.08 (0.94–1.23)
zSI1.04 (0.86–1.25)0.87 (0.75–1.01)1.03 (0.84–1.26)0.86 (0.74–1.00)0.99 (0.83–1.18)0.94 (0.83–1.06)
Normalised index + interaction
zNA0.99 (0.82–1.20)1.14 (0.97–1.33)1.01 (0.83–1.23)1.13 (0.96–1.32)0.99 (0.83–1.18)1.08 (0.95–1.24)
zSI1.03 (0.85–1.25)0.87 (0.75–1.01)1.02 (0.83–1.25)0.86 (0.74–1.00)0.99 (0.83–1.18)0.95 (0.83–1.08)
zNA × zSI1.01 (0.87–1.18)1.01 (0.90–1.13)1.04 (0.88–1.22)1.01 (0.89–1.13)1.01 (0.88–1.17)0.97 (0.87–1.08)
Complete cases analysis
Multiple imputed data analysis
Reduced modelaReduced modelbFull modelc,dFull modelc,dFull modelc,eFull modelc,e
Recurrent MIAll-cause mortalityRecurrent MIAll-cause mortalityRecurrent MIAll-cause mortality
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)f 1.17 (0.74–1.85) 1.02 (0.69–1.49) 1.27 (0.79–2.03) 0.99 (0.67–1.46) 1.07 (0.69–1.65) 0.97 (0.69–1.37)
NA ≥ 101.31 (0.91–1.89)1.18 (0.88–1.59)1.41 (0.97–2.04)1.15 (0.85–1.56)1.20 (0.86–1.69)1.12 (0.86–1.44)
SI ≥ 101.12 (0.79–1.59)0.82 (0.62–1.09)1.08 (0.74–1.57)0.81 (0.61–1.07)1.01 (0.72–1.41)0.86 (0.67–1.10)
NA (score 0–28)1.00 (0.97–1.04)1.01 (0.98–1.04)1.01 (0.97–1.04)1.01 (0.98–1.04)1.00 (0.97–1.03)1.01 (0.98–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.99 (0.96–1.01)1.01 (0.97–1.04)0.98 (0.95–1.01)1.00 (0.97–1.03)0.99 (0.97–1.02)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
zNA1.01 (0.85–1.20)1.07 (0.94–1.23)1.03 (0.86–1.23)1.06 (0.92–1.22)0.99 (0.84–1.16)1.05 (0.93–1.19)
zSI1.04 (0.87–1.23)0.92 (0.80–1.05)1.04 (0.86–1.25)0.90 (0.78–1.03)0.99 (0.84–1.17)0.96 (0.86–1.08)
zNA × zSI1.02 (0.88–1.18)1.01 (0.91–1.12)1.04 (0.90–1.21)1.00 (0.90–1.12)1.01 (0.88–1.16)0.98 (0.89–1.08)
DS-14 as multiple variablesDichotomised
NA ≥ 101.29 (0.89–1.87)1.24 (0.92–1.68)1.40 (0.96–2.05)1.22 (0.90–1.66)1.21 (0.86–1.71)1.15 (0.88–1.48)
SI ≥ 101.07 (0.75–1.53)0.79 (0.60–1.05)1.01 (0.69–1.49)0.78 (0.58–1.04)0.97 (0.69–1.37)0.84 (0.66–1.08)
Dichotomised + interaction
NA ≥ 101.46 (0.89–2.37)1.26 (0.84–1.89)1.48 (0.90–2.45)1.23 (0.81–1.85)1.31 (0.83–2.04)1.18 (0.84–1.66)
SI ≥ 101.18 (0.75–1.83)0.80 (0.57–1.11)1.06 (0.66–1.70)0.78 (0.55–1.09)1.04 (0.68–1.57)0.86 (0.64–1.15)
(NA ≥ 10) × (SI ≥ 10)f0.77 (0.37–1.59)0.98 (0.54–1.77)0.88 (0.41–1.87)0.99 (0.53–1.82)0.84 (0.42–1.66)0.93 (0.55–1.57)
Index
NA (score 0–28)1.00 (0.96–1.04)1.02 (0.99–1.06)1.00 (0.96–1.04)1.02 (0.99–1.05)1.00 (0.96–1.03)1.01 (0.99–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.98 (0.95–1.01)1.01 (0.97–1.04)0.97 (0.95–0.99)1.00 (0.96–1.03)0.99 (0.96–1.02)
Index + interaction
NA (score 0–28)1.00 (0.94–1.06)1.02 (0.97–1.07)0.99 (0.93–1.06)1.02 (0.97–1.07)0.99 (0.94–1.05)1.02 (0.98–1.07)
SI (score 0–28)1.00 (0.95–1.06)0.98 (0.93–1.02)1.00 (0.94–1.05)0.97 (0.93–1.02)1.00 (0.95–1.05)1.00 (0.96–1.03)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.00 (0.83–1.20)1.14 (0.98–1.32)1.02 (0.84–1.24)1.13 (0.97–1.31)0.99 (0.83–1.18)1.08 (0.94–1.23)
zSI1.04 (0.86–1.25)0.87 (0.75–1.01)1.03 (0.84–1.26)0.86 (0.74–1.00)0.99 (0.83–1.18)0.94 (0.83–1.06)
Normalised index + interaction
zNA0.99 (0.82–1.20)1.14 (0.97–1.33)1.01 (0.83–1.23)1.13 (0.96–1.32)0.99 (0.83–1.18)1.08 (0.95–1.24)
zSI1.03 (0.85–1.25)0.87 (0.75–1.01)1.02 (0.83–1.25)0.86 (0.74–1.00)0.99 (0.83–1.18)0.95 (0.83–1.08)
zNA × zSI1.01 (0.87–1.18)1.01 (0.90–1.13)1.04 (0.88–1.22)1.01 (0.89–1.13)1.01 (0.88–1.17)0.97 (0.87–1.08)

BMI: body mass index; CI: confidence interval; CRP: C-reactive protein; HDL: high density lipoprotein; HR: hazard ratio; NA: negative affectivity; NT-proBNP: N-terminal pro b-type natriuretic peptide; PCI: percutaneous coronary intervention; Ref: reference; SBP: systolic blood pressure; SI: social inhibition.

a

Adjusted for age, smoker, diabetes, hypertension treatment, SBP, total cholesterol, living alone, physical activity during leisure time, prior MI, PCI during index hospitalisation, heart rate, creatinine, NT-proBNP, and diuretics. Results based on 759 (80.2%) individuals with 139 (18.3%) events.

b

Adjusted for sex, age, smoker, diabetes, hypertension treatment, total cholesterol, living alone, highest education level, physical activity during leisure time, BMI, prior MI, PCI during index hospitalisation, heart rate, creatinine, CRP, NT-proBNP, and diuretics. Results based on 727 (76.8%) individuals with 250 events (34.4%).

c

Adjusted for sex, age, smoker, diabetes, hypertension treatment, SBP, total cholesterol, HDL cholesterol, immigrant, living alone, highest education level, physical activity during leisure time, BMI, prior MI, PCI during index hospitalisation, heart rate, creatinine, CRP, NT-proBNP, β-blockers, and diuretics.

d

Results based on 722 (76.3%) individuals with complete cases for all included variables, with 132 (18.3%) events for recurrent MI and 246 (34.1%) events for all-cause mortality.

e

Results based on all 946 individuals, with 166 (17.5%) events for recurrent MI and 321 (33.9%) events for all-cause mortality, using pooled estimates from 10 imputations.

f

NA ≥ 10 and SI ≥ 10 is equivalent to (NA ≥ 10) × (SI ≥ 10).

Table 4.

Multiple Cox regression models for outcomes recurrent myocardial infarction (MI) and all-cause mortality, using complete cases and multiple imputed data analyses. Significant results are given in bold.

Complete cases analysis
Multiple imputed data analysis
Reduced modelaReduced modelbFull modelc,dFull modelc,dFull modelc,eFull modelc,e
Recurrent MIAll-cause mortalityRecurrent MIAll-cause mortalityRecurrent MIAll-cause mortality
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)f 1.17 (0.74–1.85) 1.02 (0.69–1.49) 1.27 (0.79–2.03) 0.99 (0.67–1.46) 1.07 (0.69–1.65) 0.97 (0.69–1.37)
NA ≥ 101.31 (0.91–1.89)1.18 (0.88–1.59)1.41 (0.97–2.04)1.15 (0.85–1.56)1.20 (0.86–1.69)1.12 (0.86–1.44)
SI ≥ 101.12 (0.79–1.59)0.82 (0.62–1.09)1.08 (0.74–1.57)0.81 (0.61–1.07)1.01 (0.72–1.41)0.86 (0.67–1.10)
NA (score 0–28)1.00 (0.97–1.04)1.01 (0.98–1.04)1.01 (0.97–1.04)1.01 (0.98–1.04)1.00 (0.97–1.03)1.01 (0.98–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.99 (0.96–1.01)1.01 (0.97–1.04)0.98 (0.95–1.01)1.00 (0.97–1.03)0.99 (0.97–1.02)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
zNA1.01 (0.85–1.20)1.07 (0.94–1.23)1.03 (0.86–1.23)1.06 (0.92–1.22)0.99 (0.84–1.16)1.05 (0.93–1.19)
zSI1.04 (0.87–1.23)0.92 (0.80–1.05)1.04 (0.86–1.25)0.90 (0.78–1.03)0.99 (0.84–1.17)0.96 (0.86–1.08)
zNA × zSI1.02 (0.88–1.18)1.01 (0.91–1.12)1.04 (0.90–1.21)1.00 (0.90–1.12)1.01 (0.88–1.16)0.98 (0.89–1.08)
DS-14 as multiple variablesDichotomised
NA ≥ 101.29 (0.89–1.87)1.24 (0.92–1.68)1.40 (0.96–2.05)1.22 (0.90–1.66)1.21 (0.86–1.71)1.15 (0.88–1.48)
SI ≥ 101.07 (0.75–1.53)0.79 (0.60–1.05)1.01 (0.69–1.49)0.78 (0.58–1.04)0.97 (0.69–1.37)0.84 (0.66–1.08)
Dichotomised + interaction
NA ≥ 101.46 (0.89–2.37)1.26 (0.84–1.89)1.48 (0.90–2.45)1.23 (0.81–1.85)1.31 (0.83–2.04)1.18 (0.84–1.66)
SI ≥ 101.18 (0.75–1.83)0.80 (0.57–1.11)1.06 (0.66–1.70)0.78 (0.55–1.09)1.04 (0.68–1.57)0.86 (0.64–1.15)
(NA ≥ 10) × (SI ≥ 10)f0.77 (0.37–1.59)0.98 (0.54–1.77)0.88 (0.41–1.87)0.99 (0.53–1.82)0.84 (0.42–1.66)0.93 (0.55–1.57)
Index
NA (score 0–28)1.00 (0.96–1.04)1.02 (0.99–1.06)1.00 (0.96–1.04)1.02 (0.99–1.05)1.00 (0.96–1.03)1.01 (0.99–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.98 (0.95–1.01)1.01 (0.97–1.04)0.97 (0.95–0.99)1.00 (0.96–1.03)0.99 (0.96–1.02)
Index + interaction
NA (score 0–28)1.00 (0.94–1.06)1.02 (0.97–1.07)0.99 (0.93–1.06)1.02 (0.97–1.07)0.99 (0.94–1.05)1.02 (0.98–1.07)
SI (score 0–28)1.00 (0.95–1.06)0.98 (0.93–1.02)1.00 (0.94–1.05)0.97 (0.93–1.02)1.00 (0.95–1.05)1.00 (0.96–1.03)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.00 (0.83–1.20)1.14 (0.98–1.32)1.02 (0.84–1.24)1.13 (0.97–1.31)0.99 (0.83–1.18)1.08 (0.94–1.23)
zSI1.04 (0.86–1.25)0.87 (0.75–1.01)1.03 (0.84–1.26)0.86 (0.74–1.00)0.99 (0.83–1.18)0.94 (0.83–1.06)
Normalised index + interaction
zNA0.99 (0.82–1.20)1.14 (0.97–1.33)1.01 (0.83–1.23)1.13 (0.96–1.32)0.99 (0.83–1.18)1.08 (0.95–1.24)
zSI1.03 (0.85–1.25)0.87 (0.75–1.01)1.02 (0.83–1.25)0.86 (0.74–1.00)0.99 (0.83–1.18)0.95 (0.83–1.08)
zNA × zSI1.01 (0.87–1.18)1.01 (0.90–1.13)1.04 (0.88–1.22)1.01 (0.89–1.13)1.01 (0.88–1.17)0.97 (0.87–1.08)
Complete cases analysis
Multiple imputed data analysis
Reduced modelaReduced modelbFull modelc,dFull modelc,dFull modelc,eFull modelc,e
Recurrent MIAll-cause mortalityRecurrent MIAll-cause mortalityRecurrent MIAll-cause mortality
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)
DS-14 as single variablesType D personality (NA ≥ 10 and SI ≥ 10)f 1.17 (0.74–1.85) 1.02 (0.69–1.49) 1.27 (0.79–2.03) 0.99 (0.67–1.46) 1.07 (0.69–1.65) 0.97 (0.69–1.37)
NA ≥ 101.31 (0.91–1.89)1.18 (0.88–1.59)1.41 (0.97–2.04)1.15 (0.85–1.56)1.20 (0.86–1.69)1.12 (0.86–1.44)
SI ≥ 101.12 (0.79–1.59)0.82 (0.62–1.09)1.08 (0.74–1.57)0.81 (0.61–1.07)1.01 (0.72–1.41)0.86 (0.67–1.10)
NA (score 0–28)1.00 (0.97–1.04)1.01 (0.98–1.04)1.01 (0.97–1.04)1.01 (0.98–1.04)1.00 (0.97–1.03)1.01 (0.98–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.99 (0.96–1.01)1.01 (0.97–1.04)0.98 (0.95–1.01)1.00 (0.97–1.03)0.99 (0.97–1.02)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
zNA1.01 (0.85–1.20)1.07 (0.94–1.23)1.03 (0.86–1.23)1.06 (0.92–1.22)0.99 (0.84–1.16)1.05 (0.93–1.19)
zSI1.04 (0.87–1.23)0.92 (0.80–1.05)1.04 (0.86–1.25)0.90 (0.78–1.03)0.99 (0.84–1.17)0.96 (0.86–1.08)
zNA × zSI1.02 (0.88–1.18)1.01 (0.91–1.12)1.04 (0.90–1.21)1.00 (0.90–1.12)1.01 (0.88–1.16)0.98 (0.89–1.08)
DS-14 as multiple variablesDichotomised
NA ≥ 101.29 (0.89–1.87)1.24 (0.92–1.68)1.40 (0.96–2.05)1.22 (0.90–1.66)1.21 (0.86–1.71)1.15 (0.88–1.48)
SI ≥ 101.07 (0.75–1.53)0.79 (0.60–1.05)1.01 (0.69–1.49)0.78 (0.58–1.04)0.97 (0.69–1.37)0.84 (0.66–1.08)
Dichotomised + interaction
NA ≥ 101.46 (0.89–2.37)1.26 (0.84–1.89)1.48 (0.90–2.45)1.23 (0.81–1.85)1.31 (0.83–2.04)1.18 (0.84–1.66)
SI ≥ 101.18 (0.75–1.83)0.80 (0.57–1.11)1.06 (0.66–1.70)0.78 (0.55–1.09)1.04 (0.68–1.57)0.86 (0.64–1.15)
(NA ≥ 10) × (SI ≥ 10)f0.77 (0.37–1.59)0.98 (0.54–1.77)0.88 (0.41–1.87)0.99 (0.53–1.82)0.84 (0.42–1.66)0.93 (0.55–1.57)
Index
NA (score 0–28)1.00 (0.96–1.04)1.02 (0.99–1.06)1.00 (0.96–1.04)1.02 (0.99–1.05)1.00 (0.96–1.03)1.01 (0.99–1.04)
SI (score 0–28)1.01 (0.97–1.04)0.98 (0.95–1.01)1.01 (0.97–1.04)0.97 (0.95–0.99)1.00 (0.96–1.03)0.99 (0.96–1.02)
Index + interaction
NA (score 0–28)1.00 (0.94–1.06)1.02 (0.97–1.07)0.99 (0.93–1.06)1.02 (0.97–1.07)0.99 (0.94–1.05)1.02 (0.98–1.07)
SI (score 0–28)1.00 (0.95–1.06)0.98 (0.93–1.02)1.00 (0.94–1.05)0.97 (0.93–1.02)1.00 (0.95–1.05)1.00 (0.96–1.03)
NA × SI1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)1.00 (0.99–1.01)
Normalised index
zNA1.00 (0.83–1.20)1.14 (0.98–1.32)1.02 (0.84–1.24)1.13 (0.97–1.31)0.99 (0.83–1.18)1.08 (0.94–1.23)
zSI1.04 (0.86–1.25)0.87 (0.75–1.01)1.03 (0.84–1.26)0.86 (0.74–1.00)0.99 (0.83–1.18)0.94 (0.83–1.06)
Normalised index + interaction
zNA0.99 (0.82–1.20)1.14 (0.97–1.33)1.01 (0.83–1.23)1.13 (0.96–1.32)0.99 (0.83–1.18)1.08 (0.95–1.24)
zSI1.03 (0.85–1.25)0.87 (0.75–1.01)1.02 (0.83–1.25)0.86 (0.74–1.00)0.99 (0.83–1.18)0.95 (0.83–1.08)
zNA × zSI1.01 (0.87–1.18)1.01 (0.90–1.13)1.04 (0.88–1.22)1.01 (0.89–1.13)1.01 (0.88–1.17)0.97 (0.87–1.08)

BMI: body mass index; CI: confidence interval; CRP: C-reactive protein; HDL: high density lipoprotein; HR: hazard ratio; NA: negative affectivity; NT-proBNP: N-terminal pro b-type natriuretic peptide; PCI: percutaneous coronary intervention; Ref: reference; SBP: systolic blood pressure; SI: social inhibition.

a

Adjusted for age, smoker, diabetes, hypertension treatment, SBP, total cholesterol, living alone, physical activity during leisure time, prior MI, PCI during index hospitalisation, heart rate, creatinine, NT-proBNP, and diuretics. Results based on 759 (80.2%) individuals with 139 (18.3%) events.

b

Adjusted for sex, age, smoker, diabetes, hypertension treatment, total cholesterol, living alone, highest education level, physical activity during leisure time, BMI, prior MI, PCI during index hospitalisation, heart rate, creatinine, CRP, NT-proBNP, and diuretics. Results based on 727 (76.8%) individuals with 250 events (34.4%).

c

Adjusted for sex, age, smoker, diabetes, hypertension treatment, SBP, total cholesterol, HDL cholesterol, immigrant, living alone, highest education level, physical activity during leisure time, BMI, prior MI, PCI during index hospitalisation, heart rate, creatinine, CRP, NT-proBNP, β-blockers, and diuretics.

d

Results based on 722 (76.3%) individuals with complete cases for all included variables, with 132 (18.3%) events for recurrent MI and 246 (34.1%) events for all-cause mortality.

e

Results based on all 946 individuals, with 166 (17.5%) events for recurrent MI and 321 (33.9%) events for all-cause mortality, using pooled estimates from 10 imputations.

f

NA ≥ 10 and SI ≥ 10 is equivalent to (NA ≥ 10) × (SI ≥ 10).

RMI

During a mean (SD) follow-up time of 5.7 (3.2) years (5364 person-years), 166 (17.5%) patients suffered RMI, with 26 (15.7%) having TDP (NA ≥ 10 and SI ≥ 10). No DS14 variable was significantly associated with RMI. However, in the basic model (Table 3), age, diabetes, hypertension treatment, SBP, total cholesterol, physical activity during leisure time, prior MI, heart rate, creatinine, NT-proBNP, and diuretics were all significantly associated with risk of RMI.

ACM

During a mean (SD) follow-up time of 6.3 (2.9) years (5933 person-years), 321 deaths (33.9%) occurred, with 42 (13.1%) of the deceased having TDP (NA ≥ 10 and SI ≥ 10). In the basic regression model (Table 3), only SI and zSI were significantly associated with ACM, with HRs (95% CI) of 1.02 (1.00–1.05) and 1.14 (1.02–1.27), respectively, implying 2% and 14% higher risks of early death for each increase in index score in the case of including these as single variables. Adjusting for NA and zNA, respectively, resulted in HRs (95% CI) of 1.02 (1.00–1.05) and 1.15 (1.02–1.29) for SI and zSI, implying 2% and 15% higher risks of early death for each increase in index score, although in these cases neither NA nor zNA were significantly associated with ACM. Likewise, zSI was still significantly associated with ACM after adjusting for zNA and zNA × zSI, HR (95% CI) 1.15 (1.02–1.30), but since zNA × zSI was far from statistically significant, it was not included in the model. All secondary risk factors except SBP, HDL cholesterol, immigrant, and β-blockers were significantly associated with risk of early death.

In the multiple regression models (Table 4), no DS14 variable was significantly associated with ACM when included as single variables, but both SI and zSI were significantly associated with ACM in the full model, after adjusting for NA and zNA, respectively. Notably, with HRs (95% CI) of 0.97 (0.95–0.99) and 0.86 (0.74–1.00), respectively, each increase in index score for SI and zSI implied 3% and 14% lower risks of early death. Again, neither NA nor zNA had any significant association with ACM in these cases, and zSI was still significantly associated with ACM after adjusting for zNA and zNA × zSI, HR (95% CI) 0.86 (0.74–1.00), with zNA × zSI not being statistically significant. However, when using the reduced or multiple imputed full models, no DS14 variable was significantly associated with ACM when including DS14 as multiple variables (Table 4).

Discussion

The present study found no support for TDP being independently associated with RMI or ACM in post-acute MI patients, using any of the previously proposed methods for measuring TDP. A association was found between the SI part of TDP and a decreased risk of ACM when adjusting for all risk factors, but this association was not significant in a multiple imputation analysis.

Whereas some studies have suggested an association between TDP and major adverse cardiac events, the findings are inconsistent,6,9,10,14,32 giving ambiguous evidence regarding whether TDP is related to RMI or mortality in CHD patients. Consequently, it was important to assess whether TDP could be useful after adjusting for established risk factors.

The results of the present study is consistent with previous studies finding no evidence for TDP implying an increased risk of RMI/adverse cardiac events or early death.23,25 According to recent findings, TDP is associated with an increased risk of cardiac events, but not with non-cardiac death, nor with events in patients aged ≥70 years.33 Although several researchers have investigated the clinical importance of TDP, the arbitrary cut-off values have been criticised.14 Thus, for example, Dulfer et al.29 found that zNA × zSI was not associated with 10-year ACM in PCI patients, whereas dichotomous TDP (NA ≥ 10 and SI ≥ 10) was.

Previous studies finding an association between TDP and mortality were often based on small samples with few events.6,8,17,34 The present study was based on 166 RMI and 321 ACM events, suggesting that the null findings of this study were probably plausible.

It is possible that the effects of TDP, due to specific aetiological mechanisms on the cardiovascular system, are more related to cardiac mortality than ACM. However, considering that the population in the present study suffered from CHD, and the strong association observed between the cardiovascular risk factors and ACM, if this effect existed, it should have had an impact on ACM in the present study. However, despite the findings in the present study, patients with clinically significant symptoms of distress following MI should be referred to psychological counselling or psychologically focused interventions.35

Strengths and limitations

Strengths of the present study included the relatively large population used, the long-term follow-up, and the incorporation of all previously proposed methods for measuring TDP. Another limitation was the relatively high level of troponin I ≥ 0.4 µg/l used as a diagnostic marker. Some of the patients had suffered from a prior MI at inclusion, and an association between TDP and first ever incident AMI may thus not be ruled out. Moreover, ACM may not be comparable with cardiac mortality. Studies have shown associations between TDP and cardiac mortality, but not between TDP and ACM. A final limitation was the high mean age (>70 years) in the present study, since the importance of TDP may be more pronounced in younger patients.

Conclusions

No support was found for TDP being independently associated with RMI or ACM in post-acute MI patients, using any of the previously proposed methods for measuring TDP.

Author contribution

JL designed the VaMIs study, EC and AR were involved in the design of the study, the analysis and interpretation of the data, and drafting the manuscript. PW was involved in the analysis. JL, LE and CÅ made substantial contributions to the design and revised the manuscript critically. All authors gave their approval to publish the manuscript.

Acknowledgements

The authors thank Marja-Leena Ojutkangas, Annika Kärnsund and Mattias Rehn for data collection and management.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by grants from SparbanksstiftelsenNya, the Swedish Council for Working Life and Social Research, and the Västmanland County Council. Funding was not associated with any conditions regarding the design, execution, or interpretation of the study, nor regarding the decision to publish the manuscript.

References

1

World Health Organization
.
Global status report on noncommunicable diseases 2010
,
Geneva
:
World Health Organization
,
2011
.

2

Kozela
M
,
Bobak
M
,
Besala
A
et al. .
The association of depressive symptoms with cardiovascular and all-cause mortality in Central and Eastern Europe: Prospective results of the HAPIEE study
.
Eur J Prev Cardiol
 
2016
;
23
:
1839
1847
.

3

Denollet
J
.
DS14: Standard assessment of negative affectivity, social inhibition, and type D personality
.
Psychosom Med
 
2005
;
67
:
89
97
.

4

Zuccarella-Hackl
C
,
von Kanel
R
,
Thomas
L
et al. .
Higher macrophage superoxide anion production in coronary artery disease (CAD) patients with type D personality
.
Psychoneuroendocrinology
 
2016
;
68
:
186
193
.

5

Denollet
J
,
Martens
EJ
,
Smith
OR
et al. .
Efficient assessment of depressive symptoms and their prognostic value in myocardial infarction patients
.
J Affect Disord
 
2010
;
120
:
105
111
.

6

Denollet
J
,
Sys
SU
,
Stroobant
N
et al. .
Personality as independent predictor of long-term mortality in patients with coronary heart disease
.
Lancet
 
1996
;
347
:
417
421
.

7

Pedersen
SS
,
van den Broek
KC
,
Erdman
RA
et al. .
Pre-implantation implantable cardioverter defibrillator concerns and type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator
.
Europace
 
2010
;
12
:
1446
1452
.

8

Denollet
J
,
Holmes
RV
,
Vrints
CJ
et al. .
Unfavorable outcome of heart transplantation in recipients with type D personality
.
J Heart Lung Transplant
 
2007
;
26
:
152
158
.

9

Denollet
J
,
Pedersen
SS
,
Vrints
CJ
et al. .
Predictive value of social inhibition and negative affectivity for cardiovascular events and mortality in patients with coronary artery disease: The type D personality construct
.
Psychosom Med
 
2013
;
75
:
873
881
.

10

Pelle
AJ
,
Pedersen
SS
,
Schiffer
AA
et al. .
Psychological distress and mortality in systolic heart failure
.
Circ Heart Fail
 
2010
;
3
:
261
267
.

11

De Voogd
JN
,
Wempe
JB
,
Postema
K
et al. .
More evidence that depressive symptoms predict mortality in COPD patients: Is type D personality an alternative explanation?
 
Ann Behav Med
 
2009
;
38
:
86
93
.

12

Volz
A
,
Schmid
JP
,
Zwahlen
M
et al. .
Predictors of readmission and health related quality of life in patients with chronic heart failure: A comparison of different psychosocial aspects
.
J Behav Med
 
2011
;
34
:
13
22
.

13

Williams
L
,
O'Connor
RC
,
Grubb
NR
et al. .
Type D personality and three-month psychosocial outcomes among patients post-myocardial infarction
.
J Psychosom Res
 
2012
;
72
:
422
426
.

14

Coyne
JC
,
Jaarsma
T
,
Luttik
ML
et al. .
Lack of prognostic value of type D personality for mortality in a large sample of heart failure patients
.
Psychosom Med
 
2011
;
73
:
557
562
.

15

Ferguson
E
,
Williams
L
,
O'Connor
RC
et al. .
A taxometric analysis of type-D personality
.
Psychosom Med
 
2009
;
71
:
981
986
.

16

Smith
TW
.
Toward a more systematic, cumulative, and applicable science of personality and health: Lessons from type D personality
.
Psychosom Med
 
2011
;
73
:
528
532
.

17

Denollet
J
,
Vaes
J
,
Brutsaert
DL
.
Inadequate response to treatment in coronary heart disease: Adverse effects of type D personality and younger age on 5-year prognosis and quality of life
.
Circulation
 
2000
;
102
:
630
635
.

18

Pedersen
SS
,
Lemos
PA
,
van Vooren
PR
et al. .
Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: A Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry substudy
.
J Am Coll Cardiol
 
2004
;
44
:
997
1001
.

19

Denollet
J
,
Pedersen
SS
,
Vrints
CJ
et al. .
Usefulness of type D personality in predicting five-year cardiac events above and beyond concurrent symptoms of stress in patients with coronary heart disease
.
Am J Cardiol
 
2006
;
97
:
970
973
.

20

Denollet
J
,
Pedersen
SS
,
Ong
AT
et al. .
Social inhibition modulates the effect of negative emotions on cardiac prognosis following percutaneous coronary intervention in the drug-eluting stent era
.
Eur Heart J
 
2006
;
27
:
171
177
.

21

Denollet
J
,
Pedersen
SS
.
Prognostic value of type D personality compared with depressive symptoms
.
Arch Intern Med
 
2008
;
168
:
431
432
.

22

Aquarius
AE
,
Smolderen
KG
,
Hamming
JF
et al. .
Type D personality and mortality in peripheral arterial disease: A pilot study
.
Arch Surg
 
2009
;
144
:
728
733
.

23

Martens
EJ
,
Mols
F
,
Burg
MM
et al. .
Type D personality predicts clinical events after myocardial infarction, above and beyond disease severity and depression
.
J Clin Psychiatry
 
2010
;
71
:
778
783
.

24

Schiffer
AA
,
Smith
OR
,
Pedersen
SS
et al. .
Type D personality and cardiac mortality in patients with chronic heart failure
.
Int J Cardiol
 
2010
;
142
:
230
235
.

25

Grande
G
,
Romppel
M
,
Vesper
JM
et al. .
Type D personality and all-cause mortality in cardiac patients – data from a German cohort study
.
Psychosom Med
 
2011
;
73
:
548
556
.

26

Damen
NL
,
Versteeg
H
,
Boersma
E
et al. .
Depression is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: Results from the RESEARCH registry
.
Int J Cardiol
 
2013
;
167
:
2496
2501
.

27

Denollet
J
,
Tekle
FB
,
van der Voort
PH
et al. .
Age-related differences in the effect of psychological distress on mortality: Type D personality in younger versus older patients with cardiac arrhythmias
.
Biomed Res Int
 
2013
;
2013
:
246035
246035
.

28

Meyer
T
,
Hussein
S
,
Lange
HW
et al. .
Type D personality is unrelated to major adverse cardiovascular events in patients with coronary artery disease treated by intracoronary stenting
.
Ann Behav Med
 
2014
;
48
:
156–162
156–162
.

29

Dulfer
K
,
Hazemeijer
BA
,
Van Dijk
MR
et al. .
Prognostic value of type D personality for 10-year mortality and subjective health status in patients treated with percutaneous coronary intervention
.
J Psychosom Res
 
2015
;
79
:
214
221
.

30

Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502–1513.

31

Conden
E
,
Rosenblad
A
,
Ekselius
L
et al. .
Prevalence of type D personality and factorial and temporal stability of the DS14 after myocardial infarction in a Swedish population
.
Scand J Psychol
 
2014
;
55
:
601
610
.

32

Coyne
JC
,
de Voogd
JN
.
Are we witnessing the decline effect in the type D personality literature? What can be learned?
 
J Psychosom Res
 
2012
;
73
:
401
407
.

33

Kupper
N
,
Denollet
J
.
Explaining heterogeneity in the predictive value of type D personality for cardiac events and mortality
.
Int J Cardiol
 
2016
;
224
:
119
124
.

34

Pedersen
SS
,
Denollet
J
,
Ong
AT
et al. .
Adverse clinical events in patients treated with sirolimus-eluting stents: The impact of type D personality
.
Eur J Cardiovasc Prev Rehabil
 
2007
;
14
:
135
140
.

35

Pogosova
N
,
Saner
H
,
Pedersen
SS
et al. .
Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology
.
Eur J Prev Cardiol
 
2015
;
22
:
1290
1306
.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.